COVID-19 HCP Letter
Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre
Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*
TAKHZYRO® (lanadelumab injection) receives positive recommendation from CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of hereditary angioedema (HAE) attacks
© 2020 Takeda Canada Inc. All rights reserved.
You are about to leave the Takeda Canada website. This link is provided by Takeda as a resource to website visitors. Takeda Canada does not endorse or take responsibility for information presented on any website except its own.
Do you wish to leave this site?